A Phase I Study of the Safety and Pharmacokinetics of a Fully Human Monoclonal Antibody to the Vascular Endothelial Growth Factor Receptor2 (Tanibirumab) in Patients With Advanced Cancers or Metastatic Cancer
Phase of Trial: Phase I
Latest Information Update: 08 Apr 2017
Price : $35 *
At a glance
- Drugs Olinvacimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 08 Apr 2017 Results published in the Investigational New Drugs
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 27 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.